Related Experiment Video
Updated: Sep 22, 2025
Capturing the Interaction Kinetics of an Ion Channel Protein with Small Molecules by the Bio-layer Interferometry Assay
Published on: March 7, 2018
Targeting Lipid-Ion Channel Interactions in Cardiovascular Disease
Emma C Hudgins1, Adam M Bonar1, Thanh Nguyen1
1Department of Kinesiology and Applied Physiology, College of Health Sciences, University of Delaware, Newark, DE, United States.
Abstract:
General lipid-lowering strategies exhibit clinical benefit, however, adverse effects and low adherence of relevant pharmacotherapies warrants the investigation into distinct avenues for preventing dyslipidemia-induced cardiovascular disease. Ion channels play an important role in the maintenance of vascular tone, the impairment of which is a critical precursor to disease progression. Recent evidence suggests that the dysregulation of ion channel function in dyslipidemia is one of many contributors to the advancement of cardiovascular disease thus bringing to light a novel yet putative therapeutic avenue for preventing the progression of disease mechanisms. Increasing evidence suggests that lipid regulation of ion channels often occurs through direct binding of the lipid with the ion channel thereby creating a potential therapeutic target wherein preventing specific lipid-ion channel interactions, perhaps in combination with established lipid lowering therapies, may restore ion channel function and the proper control of vascular tone. Here we first detail specific examples of lipid-ion channel interactions that promote vascular dysfunction and highlight the benefits of preventing such interactions. We next discuss the putative therapeutic avenues, such as peptides, monoclonal antibodies, and aspects of nanomedicine that may be utilized to prevent pathological lipid-ion channel interactions. Finally, we discuss the experimental challenges with identifying lipid-ion channel interactions as well as the likely pitfalls with developing the aforementioned putative strategies.
Insights
Dyslipidemia impairs vascular tone by altering ion channel function. Targeting lipid-ion channel interactions offers a novel therapeutic strategy to prevent cardiovascular disease progression.
Area of Science:
- Cardiovascular Science
- Molecular Biology
- Pharmacology
Background:
- Dyslipidemia contributes to cardiovascular disease (CVD) through various mechanisms.
- Ion channel dysfunction in dyslipidemia impairs vascular tone, a key factor in CVD progression.
- Current lipid-lowering therapies have limitations, necessitating novel therapeutic approaches.
Purpose of the Study:
- To explore the role of lipid-ion channel interactions in dyslipidemia-induced vascular dysfunction.
- To identify potential therapeutic strategies targeting these interactions for CVD prevention.
- To discuss challenges and future directions in developing these novel therapies.
Main Methods:
- Review of existing literature on lipid-ion channel interactions and their impact on vascular tone.
- Analysis of specific examples of pathological lipid-ion channel binding.
- Discussion of potential therapeutic modalities including peptides, monoclonal antibodies, and nanomedicine.
Main Results:
- Lipid regulation of ion channels directly impacts vascular tone, contributing to CVD.
- Preventing specific pathological lipid-ion channel interactions may restore vascular function.
- Several therapeutic avenues, including peptides and antibodies, show promise for intervention.
Conclusions:
- Targeting lipid-ion channel interactions represents a promising novel strategy for preventing dyslipidemia-induced cardiovascular disease.
- Further research is needed to overcome experimental challenges in identifying these interactions and developing effective therapies.
- Combination therapies, integrating lipid-ion channel modulation with existing treatments, may offer enhanced clinical benefits.
More Related Videos
Related Concept Videos
01:26Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
01:30Ligand-Gated Ion Channel Receptor: Gating Mechanism
01:26Atherosclerosis III: Management
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents